AbbVie · 1 week ago
2026 Preclinical Study Design & Assay Development Intern
Branchburg, NJ
Internship
Onsite
Intern
$20/hr - $36/hr
Start in 2026 SummerAbbVie is a pharmaceutical company dedicated to discovering and delivering innovative medicines. They are seeking a motivated intern to support their Regenerative Medicine group by assisting in the design and execution of preclinical studies and optimizing in vitro assays related to tissue engineering and biomaterials research.
BiotechnologyFinancial ServicesHealth CareMedicalPharmaceuticalVenture Capital
Responsibilities
Support pre-clinical study planning, data collection, and documentation
Assist in developing and validating in vitro testing assays
Collaborate with scientists to optimize experimental protocols
Perform literature reviews and help analyze experimental data
Present findings in team meetings and prepare technical reports
Qualification
Required
Currently enrolled in university, pursuing a Bachelor's in: Biomedical Engineering, Biology, or related field
Basic understanding of tissue engineering or materials science
Strong organizational and communication skills
Must be enrolled in university for at least one semester following the internship
Expected graduation date between December 2026 – June 2027
Preferred
Laboratory experience with cell culture, microscopy, or biochemical assays
Benefits
Competitive pay
Relocation support for eligible students
Select wellness benefits and paid holiday / sick time
Company
AbbVie
AbbVie is a biopharmaceutical company focused on immunology, oncology, neuroscience, virology, and aesthetics. It is a sub-organization of AbbVie.
Founded in 2013
10001+ employees
H1B Sponsorship
AbbVie has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (273)
2024 (190)
2023 (225)
2022 (284)
2021 (186)
2020 (186)
Funding
Current Stage
Public CompanyTotal Funding
$15B2024-02-27Post Ipo Debt· $15B
2023-03-08Post Ipo Equity· $0.25M
2012-12-20IPO
Leadership Team
Robert Michael
Chairman of the Board and Chief Executive Officer
Micah Bregman
Vice President, Global Strategy and Pipeline, Allergan Aesthetics
Recent News
2026-01-09
2026-01-09
Company data provided by crunchbase